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Introduction
Solitary fibrous tumors account for 10% of neoplasms
that arise in the pleura.1 Unlike pleural mesothelioma, in
which asbestos plays an important role, solitary tumors
of the pleura have not been clearly linked to a particular
etiological factor. Another difference between solitary
tumors and pleural mesothelioma is that most solitary
tumors are benign, only 12% proving malignant.2
Solitary fibrous tumors were once thought to arise
from mesothelial pleural cells,3 but thanks to
immunohistochemistry we now know them to be
mesenchymal, with positive CD34 and vimentin
expression and negative expression of cytokeratins and
other epithelial antigens—a profile that is the opposite
of the one seen for malignant mesothelioma.2
We describe 7 patients with solitary fibrous tumors of
the pleura treated in our hospital in order to analyze the
role of surgery.
Case Description
Seven patients were treated between 1997 and 2003 in a
total of 9 operations. Three were women and 4 men (Table 1).
Ages ranged from 25 to 63 years (mean, 52.5 years).
Three patients were asymptomatic at the time of diagnosis.
The most relevant symptoms were hypoglycemia and
acropachy, lower extremity edema and coughing, ipsilateral
arm edema, and moderate pain on the side where the mass
was located (Table 1).
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OBJECTIVE: Localized fibrous tumors of the pleura are
rare. We report 7 cases and review the literature in order to
define the range of clinical characteristics of these tumors,
treatment options, and prognosis.
METHODS: A retrospective review of 7 cases treated between
1997 and 2003, focusing on clinical presentation, diagnostic tests,
and treatment. The tumor was removed surgically in all cases,
by thoracotomy in 6 cases and by video-assisted thoracoscopic
surgery in 1 patient.
RESULTS: All patients recovered fully after surgery, with no
postoperative complications. One patient experienced recurrence
twice, 33 and 67 months after the initial resection. All are alive
at the time of writing, after a mean follow up period of 19
months (range 1 month to 5 years and 10 months).
CONCLUSIONS: The treatment of choice for a fibrous tumor
of the pleura is full resection and follow up to detect possible
late recurrence.
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Mesotelioma fibroso localizado de pleura: nuestra
experiencia quirúrgica en 7 casos recientes
OBJETIVO: El tumor fibroso localizado de pleura es una le-
sión poco frecuente. El objetivo de este artículo es presentar
7 casos propios y revisar la bibliografía existente, con el fin
de establecer el espectro clínico de estos tumores, el trata-
miento y su pronóstico.
MÉTODOS: Revisión retrospectiva de una serie de 7 casos
intervenidos entre 1997 y 2003, analizando el modo de pre-
sentación, las pruebas diagnósticas y el tratamiento. En to-
dos los casos se realizó una resección quirúrgica de la masa,
que se llevó a cabo por toracotomía en 6 de los pacientes y
por videotoracoscopia en el paciente restante.
RESULTADOS: Tras la cirugía todos los pacientes se recupe-
raron completamente, sin la presencia de complicaciones
postoperatorias. Un caso recidivó en 2 ocasiones, a los 33 y a
los 67 meses de la resección inicial. Todos ellos están vivos
en la actualidad tras un período de seguimiento medio de 19
meses (desde 1 mes a 5 años y 10 meses).
CONCLUSIONES: El tratamiento de elección del tumor fibro-
so de pleura es la resección completa con seguimiento poste-
rior, por la posibilidad de recidivas tardías de la enfermedad.
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All patients had computed tomography (CT) scans of the
chest (Figure 1) showing a mass with well-defined borders.
Pleural effusion was present in 3 cases. The lesion was
biopsied before resection in 4 cases and the results were
consistent with a diagnosis of localized fibrous tumor of the
pleura in 3 and adenocarcinoma in 1. Mean tumor size
measured at the widest point was 9.8 cm (range, 2.5 to 15 cm).
The treatment of choice was complete surgical resection of
the mass by thoracotomy in 6 cases and video-assisted
thoracoscopy in 1 case (Figure 2). No complementary
treatments were given (Table 1).
Histology of the excised tissue confirmed the diagnosis of
localized fibrous tumor of the pleura in all cases. Cell
polymorphism and a high number of mitoses in 1 patient
suggested the possibility of malignant progression. The most
representative results of antigen marker studies in the patients
for whom they were ordered were positive vimentin and Bcl-2
expression and negative cytokeratin expression in all patients
and CD34 positivity in 66% (Table 2).
One patient experienced recurrence even though histology
suggested the tumor was benign. The first recurrence was 33
months after resection of the first tumor and the second
recurrence occurred 33 months after the second tumor
resection. Both recurrences were treated by surgical
resection.
Discussion
Localized fibrous tumors of the pleura are fairly rare.
Although they have been reported in patients as young
as 5 years of age and as old as 87 years, most appear in
the sixth and seventh decades of life, with fairly equal
frequency in men and women.4 Clinical presentation
varies and diagnosis is fortuitous in 50% of cases.1
Three of our 7 patients were asymptomatic at the time
of diagnosis. Symptoms arise mainly because local
spread of the mass causes coughing (33%), chest pain
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Figure 1. Computed tomography scan of the chest in which a large,
heterogeneous mass with well-defined borders can be seen occupying
nearly the entire left side of the thorax, displacing mediastinal structures.
Figure 2. Videothoracoscopic view. The endostapler (E) can be seen
starting to section the pedicle of the tumor (PT). The arrow shows the
macroscopic border between the tumor (T) and its pedicle. The lung
parenchyma (P) is located to the left of the mass. 
TABLE 1
Clinical Findings*
Case Sex/Age, Years Signs/Symptoms Computed Tomography Size, cm Biopsy
1 Male/63 Asymptomatic Mass, left lower quadrant 15×9×8 Consistent with SFTP
Microcalcifications
Pleural effusion
2 Female/25 Edema, upper left arm Mass, left upper quadrant 13×12×10 Consistent with SFTP 
and benign pleural 
tumor
Calcifications, cystic areas
3 Male/63 Asymptomatic Nodule, right upper lobe 2.5×2
Pleural effusion
4 Female/50 Moderate pain, right side Mass, right lower quadrant 11×10×5,5 Adenocarcinoma
5 Male/52 Edema, lower extremities; Mass, right lower quadrant 7.5×7×3.5
cough
6 Male/58 Asymptomatic Mass, juxtadiaphragmatic, left 4.7
7 Female/57 Hypoglycemia Mass, left lower quadrant 15×15×10 Consistent with SFTP 
Pleural effusion
*SFTP indicates solitary fibrous tumor of the pleura.
(23%), breathlessness (19%), fever (17%), and less
often hemoptysis and obstructive pneumonitis. Pleural
effusion occurs in 10% of cases,2 but was seen on the
CT scans of 3 of our patients. Systemic signs are less
common: acropachy occurs in 10% to 20%,5 and insulin
growth factor II is secreted by the tumor in 5%, leading
to refractory paraneoplastic hypoglycemia that
disappears 3 or 4 days after surgery.6 One of our
patients, who also had acropachy, debuted with loss of
consciousness caused by an episode of severe
hypoglycemia. Weight loss2 and galactorrhea1 are other
possible signs of the tumor.
The diagnostic process remains complex. Simple
radiographs will reveal an intrathoracic tumor that is
round, homogeneous, solitary, and that has well-defined
borders.4 Such findings are not specific to the diagnosis,
however. A CT scan will reveal a lobulated mass with
heterogeneity that varies according to the grade of
necrosis and the presence or not of calcifications.
Magnetic resonance imaging is used to establish the
borders between the lesion and adjacent structures and
to confirm the intrathoracic location.7 The role of
positron emission tomography is currently being
debated and more experience is needed before
conclusions can be taken.8 The differential diagnosis is
wide-ranging and complex in many cases, given that
bronchogenic cysts, pulmonary abscesses, other lung
and pleural neoplasms, lipomas, sarcomas, and
malignant fibrous histiocytomas, among other entities,
can have similar clinical and radiographic signs.9
Transthoracic CT-guided biopsy does not seem to be a
reliable diagnostic method10: given the heterogeneous
distribution of cellular density within the tumor, the
material obtained by this method may be insufficient.11
However, some authors consider it to be of great
diagnostic value.12 In our experience, in 3 of the 4
biopsies performed, the diagnosis was congruent with
the study of the excised tissue. Many authors insist that
surgery is the only method for reaching a firm diagnosis
through histology of the resected tissue.
One of the main concerns after diagnosing a localized
fibrous pleural mass is to try to predict how it will
behave. Currently, no specific test is available for
achieving that goal. Traditionally, radiographic findings
have been described as suggesting the tumor is benign or
malignant. Likewise, cytogenetic studies have attempted
to determine the alterations that are responsible for the
tumor’s greater or lesser capacity to invade surrounding
tissue; among the markers suggested, p53 and Ki-67
have been found to be particularly important.13 The
importance of differentiating between benign and
malignant localized fibrous tumors lies in the difference
in recurrence rates for the 2 types. Only 2% of benign
tumors recur locally,3 although recurrence has been
reported as long as 17 years after resection of the primary
tumor.6 Metastasis is very rare.3 However, the tumor’s
behavior does not always correlate with histology, given
that a lesion may degenerate as time passes, to become
malignant.4 In one of the cases we report, in which
histology suggested that the mass would not behave
aggressively, it nevertheless recurred twice. Briselli et al2
described tumor size, the presence or absence of necrosis
in the excised tissue, cell polymorphism, the number of
mitoses, and resectability as being useful prognostic
factors, although the growth pattern may be the most
important predictor, even stronger than histologic
features. Egland et al4 affirmed that whether the tumor
could be fully resected or not is the factor that indicates
magnitude of risk. De Perrot et al9 reviewed 185 cases
and proposed a system of staging based on morphologic
and histologic features of the tumor, divided in 5 stages
(0 to IV), each with a distinct prognosis.
The consensus is that full resection of the tumor is
the treatment of choice in all cases and, if possible, with
a margin of safety of 1 to 2 cm.12 Adjuvant treatment
with chemo- and radiotherapy is controversial, partly
because experience is still limited. Chemo- and
radiotherapy have been reported as prolonging survival
in patients whose tumor was not fully resectable at
presentation.15 De Perrot et al9 established a treatment
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TABLE 2
Interventions and Clinical Course*
Case Approach Immunohistochemistry Clinical Course
1 Left posterolateral thoracotomy Vimentin +, CD34 –, S100 –, LCA–, cytokeratin – Local recurrence, 2.8 years; 
second local recurrence, 
5.6 years
2 Left, extended axillary thoracotomy Vimentin +, S100 +, CD34 –, pancytokeratin – Asymptomatic
3 Right posterolateral thoracotomy CD34 +, S100 –, CD68 –, keratin –, actin – Asymptomatic
4 Right posterolateral thoracotomy Vimentin +, CD99 +, Bcl-2 +, CD68+, CAM 5.2 – Asymptomatic
5 Right posterolateral thoracotomy Vimentin +, CD34 + Asymptomatic
6 Left video-assisted thoracoscopy Bcl-2 +, CD34 +, cytokeratin AE3/AE1 – Asymptomatic
7 Left posterolateral thoracotomy Ki-67 (10%), CD34 +, Bcl-2 +, Asymptomatic
thrombomodulin +, calretinin –, MOC31 –, 
carcinoembryonic antigen–, TTF1 –
*LCA indicates leukocyte common antigen; CAM, cell adhesion molecule, TTF, thyroid transcription factor.
algorithm based on the aforementioned 5-stage criteria,
with indications that complementary treatments may be
beneficial for the patient after resection of malignant
and sessile tumors. Based on our experience, we have
concluded that the treatment of choice for these tumors
at present is surgery and that more evidence is needed
before more precise conclusions can be reached
regarding complementary treatments.
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